Urethral dosimetry and toxicity with high-dose-rate interstitial brachytherapy for vaginal cancer

This study is among the first to assess urethral dosimetry for patients treated with HDR-BT for vaginal cancer. Patients who received five fractions of higher than 5 Gy/fraction to 0.1 cm3 of urethra (estimated EQD2 of 85 Gy) are at increased risk of severe urethral toxicity.